naloxegol (movantik) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
MOVANTIK (naloxegol) is a peripherally-acting mu-opioid receptor antagonist indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic noncancer pain. It is being investigated for the treatment of constipation as a side effect of prescription opioid pain medicines.   NCATS

Chemistry

  • SMILES: C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](OCCOCCOCCOCCOCCOCCOCCOC)CC[C@@]3(O)[C@H]1C5
  • InChIKey: XNKCCCKFOQNXKV-ZRSCBOBOSA-N
  • Mol. Mass: 651.79
  • ALogP: 1.86
  • ChEMBL Molecules:
    naloxegol  
    naloxegol oxalate  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$8.7663 - $11.6699
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

(5α,6α)-17-allyl-6-[(20-hydroxy-3,6,9,12,15,18-hexaoxaicos-1-yl)oxy]-4,5-epoxymorphinan-3,14-diol | az-13337019 oxalate | movantik | moventig | naloxegol | naloxegol oxalate | nktr-118 | nktr-118-oxalate

Organizations (25)

Research & Development (22)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (22)

Approved Indications (2)


 

Cancer Pain

Constipation (approved 2014)

Experimental Indications - Clinical Trial Phases 1-4 (21)


 

Analgesics, Opioid (Phase 2)

Biological Availability (Phase 1)

Brain Injuries (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Constipation (Phase 4)

Critical Illness (Phase 3)

Cystostomy (Phase 2)

Drug Interactions (Phase 1)

Drugs, Investigational (Phase 1)

Esophageal Diseases (Phase 2)

Gastroparesis (Phase 2)

Healthy Volunteers (Phase 1)

Heart Diseases (Phase 1)

Kidney Failure, Chronic (Phase 1)

Liver Diseases (Phase 1)

Neoplasms (Phase 4)

Opioid-Induced Constipation (Phase 4)

Opioid-Related Disorders (Phase 2)

Pain (Phase 4)

Pain, Postoperative (Phase 4)

Urinary Bladder Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 35
  • # of Trial Organizations: 22

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue